Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Proteomics Changes Name to Prolexys Pharmaceuticals

NEW YORK, Sept. 22 (GenomeWeb News) - Myriad Proteomics said today that it has changed its name to Prolexys Pharmaceuticals to more accurately represent its strategic focus "after making the conversion from a technology-focused organization to a drug discovery company."

Prolexys plans to use information about protein interactions to discover and validate new drug targets.

"Our new name, Prolexys, culminates the organizational and strategic transformation that has occurred here," said Thomas Ingolia, president and CEO. "As we continue to obtain disease biology information through the use of high-throughput proteomics technologies, we are taking a number of pathway discoveries through the process of validation, screening, and lead compound identification."

Ingolia said the company is focusing on neurodegenerative diseases and oncology.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more